Skip to content
MMetabolicMomsTHE MAGAZINE FOR MOTHERS ON GLP-1
Menu

Essay

Coming Off a GLP-1: Maintenance and the Rebound Question

What the withdrawal trials really show about regaining weight after stopping a GLP-1 — and how a mother can plan a pause or an exit deliberately.

By Margaux Ellery, Editor-in-Chiefa mother on the MetabolicMoms desk, not a treating clinician

Fact-checked against the record by Reed Ellsworth, who reviews the evidence as a former pharma-industry analyst — never as your clinician.

On this page

The question underneath all the other questions

Every woman I have talked to about these drugs arrives, sooner or later, at the same quiet fear. Not the nausea. Not the injections. Not even the cost, though that one is loud. The fear is this: what happens when I stop? It is the question underneath all the other questions, and it deserves a straight answer rather than a reassuring one. Because the honest answer is that stopping a GLP-1 is not like finishing a course of antibiotics. For most people, the medication is doing a job that the body resumes doing its own way the moment the drug leaves — and that resumption has a name in the search bars: rebound weight.

Let us report it plainly, then talk about what to actually do with it.

What the withdrawal trials show

The evidence here is unusually clean, because researchers ran the exact experiment we all worry about: they took people who had lost weight on a GLP-1 and stopped the drug.

In the STEP 1 trial extension, participants who had lost weight on semaglutide came off it. Over the year that followed, they regained about two-thirds of the weight they had lost, and much of the improvement in blood pressure, blood sugar, and cholesterol drifted back toward where it started1. In STEP 4, people who had already lost weight were split: those who kept taking semaglutide continued losing, while those switched to placebo began climbing back2. The tirzepatide story is the same shape — in SURMOUNT-4, people who continued the drug held their loss, while those who stopped regained a substantial share of it3.

Three trials, two molecules, one lesson: these drugs work while you take them. They are not a bridge you cross and leave behind. That is not a flaw in the medicine — it is the nature of obesity as a chronic, relapsing condition. We do not expect blood-pressure pills to keep working after we stop them either. But it reframes the entire decision, and it should reframe yours.

Rebound is not willpower failing. It is biology resuming. Naming it correctly is the first step to planning around it.

Why the weight comes back

The rebound is not a moral event, and treating it as one is how good women end up ashamed of their own physiology. GLP-1 medications work in large part by turning down appetite and the relentless food-noise that governs how much we eat. Remove the drug and that signaling returns to its old set point. Hunger comes back. The body, which experiences weight loss as a threat to be corrected, nudges metabolism and appetite toward restoring what it lost. This is the same machinery that has defeated diets for a century — and it is precisely the machinery the medication was quieting.

So when the weight returns after stopping, it is not that you "failed to keep it off." It is that the thing keeping it off was removed. Naming that correctly is not permission to stay on a drug forever; it is the only honest starting point for deciding whether, when, and how to come off.

The mother's version: a planned pause

For mothers, "coming off" is often not a permanent exit but a pause — most commonly for pregnancy. GLP-1 medications are not recommended during pregnancy or while breastfeeding, and the current review of their use in pregnancy underscores that they should be stopped before conceiving, with a washout planned in advance rather than improvised4. Because each dose lingers roughly a week, the timing is arithmetic you can do ahead of time with a clinician — which is exactly the kind of plan our guide to what to tell your OB before starting is built to start.

A planned pause changes the emotional math too. If you know going in that some regain during a pregnancy is expected biology — not backsliding — you can hold the ground you care about (habits, muscle, the relationship with food) without treating the scale as a verdict. And you can plan the restart on the other side rather than waking up to it.

How to come off well — or decide not to

If you and your clinician decide to stop, a few things genuinely help, and none of them are magic:

  1. Taper rather than quit cold, if your clinician agrees. Stepping the dose down can soften the return of appetite instead of flipping it back on all at once.
  2. Bank the muscle now. Protein and resistance training during weight loss protect the lean mass that keeps your metabolism up — the same argument we make about the new body and its adjustments. Muscle you keep is regain you resist.
  3. Keep the appetite habits you built. The medication taught your kitchen new defaults — smaller portions, protein first, less grazing. Those outlast the drug if you keep practicing them.
  4. Decide in advance what triggers a restart. A pre-agreed threshold ("if I regain X, we revisit") turns a shame spiral into a clinical decision.

And sometimes the right answer is not stopping at all. If there is no medical reason to come off, the trials suggest that staying on a maintenance dose is what holds the result — and a program that can hold you steady without the cost climbing every month becomes the thing that matters most. That is a large part of why a flat-priced, both-molecules program like CoreAge Rx ranks where it does on our board of GLP-1 programs for moms: the budget survives the long haul, and a molecule switch never resets it. Before you decide either way, it is worth understanding the true cost of staying on as the dose climbs, and — if you are weighing which molecule to be on for the long run — our head-to-head on Zepbound vs. Wegovy.

Coming off a GLP-1 is not a finish line, and staying on is not a failure of discipline. Both are clinical decisions, best made on purpose and with a plan — not by the accident of a lapsed prescription. This essay is educational only and is not medical advice; make any change to your medication with your clinician.

Frequently asked questions

Will I regain the weight if I stop a GLP-1?

Most people regain a substantial share of the weight after stopping. In the STEP 1 trial extension, participants who came off semaglutide regained about two-thirds of their lost weight over the following year, and the metabolic improvements largely reversed. Tirzepatide shows the same pattern. This is biology resuming, not willpower failing — the drugs work while you take them.

How do I come off a GLP-1 for pregnancy?

GLP-1 medications are not recommended in pregnancy or while breastfeeding, so they are stopped before conceiving. Because each dose lingers about a week, you and your clinician can plan the washout timing in advance rather than improvising. Some regain during a planned pause is expected biology, not backsliding — plan the restart on the other side.

Can I keep the weight off without staying on the medication?

It is harder, but the habits the medication helped you build — protein first, smaller portions, resistance training to protect muscle — outlast the drug if you keep them. A gradual taper, banked muscle, and a pre-agreed restart threshold all help. For many people with no medical reason to stop, staying on a maintenance dose is what holds the result.

References

  1. Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/35441470/
  2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. https://pubmed.ncbi.nlm.nih.gov/33755728/
  3. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. https://pubmed.ncbi.nlm.nih.gov/38078870/
  4. Drummond RF, Seif KE, Reece EA (2025). Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. American Journal of Obstetrics and Gynecology. https://pubmed.ncbi.nlm.nih.gov/39181497/

Reported, not prescribed. Everything on this page is journalism and general education — not a diagnosis, a treatment plan, or a recommendation to start or stop any medication. Your history, hormones, and pregnancy plans are yours alone; only a licensed clinician who knows them can advise you. Talk to one before you act on anything you read here.